Cargando…
A Multinational Analysis of Mutations and Heterogeneity in PZase, RpsA, and PanD Associated with Pyrazinamide Resistance in M/XDR Mycobacterium tuberculosis
Pyrazinamide (PZA) is an important first-line drug in all existing and new tuberculosis (TB) treatment regimens. PZA-resistance in M. tuberculosis is increasing, especially among M/XDR cases. Noted issues with PZA Drug Susceptibility Testing (DST) have driven the search for alternative tests. This s...
Autores principales: | Ramirez-Busby, S. M., Rodwell, T. C., Fink, L., Catanzaro, D., Jackson, R. L., Pettigrove, M., Catanzaro, A., Valafar, F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5476565/ https://www.ncbi.nlm.nih.gov/pubmed/28630430 http://dx.doi.org/10.1038/s41598-017-03452-y |
Ejemplares similares
-
The molecular basis of pyrazinamide activity on Mycobacterium tuberculosis PanD
por: Sun, Qingan, et al.
Publicado: (2020) -
Anti-tubercular Activity of Pyrazinamide is Independent of trans-Translation and RpsA
por: Dillon, Nicholas A., et al.
Publicado: (2017) -
Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis
por: Shi, Wanliang, et al.
Publicado: (2014) -
Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis
por: Zhang, Shuo, et al.
Publicado: (2013) -
Gibbs Free Energy Calculation of Mutation in PncA and RpsA Associated With Pyrazinamide Resistance
por: Khan, Muhammad Tahir, et al.
Publicado: (2020)